🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

RecruitingPhase 1Ages 18 Years - anyAllThe Affiliated Hospital of Qingdao University
NCT06544720 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Key Inclusion Criteria: 1. Greater than or equal to 18 years of age 2. HPV associated carcinomas 3. Patients must have at least one measurable lesion defined by RECIST 1.1 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key Exclusion Criteria: 1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory. 2. Patients with active autoimmune diseases. 3. Patient has a known active Hepatitis B or Hepatitis C. 4. Other severe medical conditions that may limit subject\'s participation in this trial.
💊

What it tests

  • SCG142 TCR-T cells
📍

Where

1 site
The affiliated hosptial of qingdao university
Qingdao, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy